Online inquiry

IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12015MR)

This product GTTS-WQ12015MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets ERBB2 gene. The antibody can be applied in Breast Cancer research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001005862.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2064
UniProt ID P04626
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ERBB2, MM-302(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ12015MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9450MR IVTScrip™ mRNA-Anti-KIR3DL2, IPH4102(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA IPH4102
GTTS-WQ10930MR IVTScrip™ mRNA-Anti-APP, MABT5102A(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MABT5102A
GTTS-WQ11109MR IVTScrip™ mRNA-Anti-TNFRSF8, MDX-060(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MDX-060
GTTS-WQ1668MR IVTScrip™ mRNA-Anti-IL1B, ACZ885(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ACZ885
GTTS-WQ10377MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA LY2062430
GTTS-WQ4272MR IVTScrip™ mRNA-Anti-LINGO1, BIIB-033(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BIIB-033
GTTS-WQ30MR IVTScrip™ mRNA-Anti-S, 2130(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 2130
GTTS-WQ3518MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BART
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW